IDEXX Laboratories, Inc. (IDXX) Presents at 47th Annual Raymond James Institutional Investor Conference Prepared Remarks Transcript

IDEXX Laboratories, Inc. (IDXX) 47th Annual Raymond James Institutional Investor Conference March 2, 2026 9:15 AM ESTCompany ParticipantsJay Mazelsky ...

Tide’s Evo Tiles Are a Fresh, Overengineered Take on the Tide Pod

Tide’s Evo Tiles are lightweight, fibrous squares of detergent that simplify the laundry process—and also act as a slightly more eco-friendly alternative to the Tide Pod.

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligibl…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

IDEXX Laboratories, Inc. (IDXX) Presents at BofA Securities Animal Health Summit Transcript

BofA Securities Animal Health Summit February 26, 2026 9:50 AM ESTCompany ParticipantsAndrew Emerson - Executive VP, ...
PharmiWeb

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...
Mirage News

FDA Fully Approves Pfizer's BRAFTOVI for Metastatic CRC

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...